Linker Information
General Information of This Linker
| Linker ID |
LIN0WYMQF
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
Cys-13 ADC linker
|
|||||
| Linker Type |
Thiol-sensitive linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C71H118N14O31
|
|||||
| Isosmiles |
COCCOCCOCCOCCOCCOCCOCCOCCNC(=O)C(COC(=O)NCCC(=O)NC(CCC(=O)NC(C)C(=O)O)C(=O)O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)CCNC(=O)CCOCCNC(=O)CNC(=O)CCC(=O)NCCOCCOCCNC(=O)OCC1C2CCC#CCCC21
|
|||||
| InChI |
InChI=1S/C71H118N14O31/c1-50(68(98)99)83-60(90)10-9-54(69(100)101)84-61(91)14-17-76-70(102)116-49-55(67(97)75-20-25-107-31-32-110-35-36-112-39-40-114-42-41-113-38-37-111-34-33-109-28-27-104-2)85-66(96)47-82-65(95)46-81-64(94)45-80-63(93)44-79-58(88)13-16-72-59(89)15-22-105-23-19-74-62(92)43-78-57(87)12-11-56(86)73-18-24-106-29-30-108-26-21-77-71(103)115-48-53-51-7-5-3-4-6-8-52(51)53/h50-55H,5-49H2,1-2H3,(H,72,89)(H,73,86)(H,74,92)(H,75,97)(H,76,102)(H,77,103)(H,78,87)(H,79,88)(H,80,93)(H,81,94)(H,82,95)(H,83,90)(H,84,91)(H,85,96)(H,98,99)(H,100,101)
|
|||||
| InChIKey |
KWOLHDFWNXHYNL-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1663.792
|
Polar area
|
601.99
|
||
|
Complexity
|
1662.808743
|
xlogp Value
|
-6.8892
|
|||
|
Heavy Count
|
116
|
Rot Bonds
|
71
|
|||
|
Hbond acc
|
29
|
Hbond Donor
|
16
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
XMT-1592 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT04396340 | Clinical Status | Phase 1/2 | ||
| Clinical Description |
A phase 1b, first-in-human, dose escalation and expansion study of XMT-1592 in patients with solid tumors likely to express NAPI2B.
|
||||
References